Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

291 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
EGFR mutations detected on cytology samples by a centralized laboratory reliably predict response to gefitinib in non-small cell lung carcinoma patients.
Malapelle U, Bellevicine C, De Luca C, Salatiello M, De Stefano A, Rocco D, de Rosa N, Vitiello F, Russo S, Pepe F, Iaccarino A, Micheli P, Illiano A, Carlomagno C, Piantedosi FV, Troncone G. Malapelle U, et al. Cancer Cytopathol. 2013 Oct;121(10):552-60. doi: 10.1002/cncy.21322. Epub 2013 Jun 18. Cancer Cytopathol. 2013. PMID: 23780873 Free article.
Consistency and reproducibility of next-generation sequencing and other multigene mutational assays: A worldwide ring trial study on quantitative cytological molecular reference specimens.
Malapelle U, Mayo-de-Las-Casas C, Molina-Vila MA, Rosell R, Savic S, Bihl M, Bubendorf L, Salto-Tellez M, de Biase D, Tallini G, Hwang DH, Sholl LM, Luthra R, Weynand B, Vander Borght S, Missiaglia E, Bongiovanni M, Stieber D, Vielh P, Schmitt F, Rappa A, Barberis M, Pepe F, Pisapia P, Serra N, Vigliar E, Bellevicine C, Fassan M, Rugge M, de Andrea CE, Lozano MD, Basolo F, Fontanini G, Nikiforov YE, Kamel-Reid S, da Cunha Santos G, Nikiforova MN, Roy-Chowdhuri S, Troncone G; Molecular Cytopathology Meeting Group. Malapelle U, et al. Cancer Cytopathol. 2017 Aug;125(8):615-626. doi: 10.1002/cncy.21868. Epub 2017 May 5. Cancer Cytopathol. 2017. PMID: 28475299 Free article.
ALK and ROS1 testing on lung cancer cytologic samples: Perspectives.
Pisapia P, Lozano MD, Vigliar E, Bellevicine C, Pepe F, Malapelle U, Troncone G. Pisapia P, et al. Among authors: malapelle u. Cancer Cytopathol. 2017 Nov;125(11):817-830. doi: 10.1002/cncy.21899. Epub 2017 Jul 25. Cancer Cytopathol. 2017. PMID: 28743163 Free article. Review.
Antitumor Efficacy of Dual Blockade of EGFR Signaling by Osimertinib in Combination With Selumetinib or Cetuximab in Activated EGFR Human NCLC Tumor Models.
Della Corte CM, Ciaramella V, Cardone C, La Monica S, Alfieri R, Petronini PG, Malapelle U, Vigliar E, Pepe F, Troncone G, Castellone MD, Troiani T, Martinelli E, Ciardiello F, Morgillo F. Della Corte CM, et al. Among authors: malapelle u. J Thorac Oncol. 2018 Jun;13(6):810-820. doi: 10.1016/j.jtho.2018.02.025. Epub 2018 Mar 8. J Thorac Oncol. 2018. PMID: 29526823 Free article.
KRAS, NRAS and BRAF mutations detected by next generation sequencing, and differential clinical outcome in metastatic colorectal cancer (MCRC) patients treated with first line FIr-B/FOx adding bevacizumab (BEV) to triplet chemotherapy.
Bruera G, Pepe F, Malapelle U, Pisapia P, Mas AD, Di Giacomo D, Calvisi G, Troncone G, Ricevuto E. Bruera G, et al. Among authors: malapelle u. Oncotarget. 2018 May 29;9(41):26279-26290. doi: 10.18632/oncotarget.25180. eCollection 2018 May 29. Oncotarget. 2018. PMID: 29899858 Free PMC article.
Osimertinib.
Malapelle U, Ricciuti B, Baglivo S, Pepe F, Pisapia P, Anastasi P, Tazza M, Sidoni A, Liberati AM, Bellezza G, Chiari R, Metro G. Malapelle U, et al. Recent Results Cancer Res. 2018;211:257-276. doi: 10.1007/978-3-319-91442-8_18. Recent Results Cancer Res. 2018. PMID: 30069773 Review.
291 results